Treatment with the combination of MIA - 602 and
doxorubicin led to an increase in final tumor volume of only 256.0 % (± 10.3 %).
Not exact matches
Researchers
led by Patricia Donahoe and Xiaolong Wei of Massachusetts General Hospital and Harvard Medical School found that the common chemotherapy agent
doxorubicin actually encourages the growth of ovarian cancer stem cells.
Anthracycline drugs, such as
doxorubicin, are known to cause heart failure because they cause changes in the DNA structure of the heart muscle cells,
leading to irreversible cardiac damage.
Therapy of
doxorubicin resistant MX - 1 tumors with MIA - 602 or combination
led to significant (P < 0.05) reduction in MDR1 and NANOG gene expression relative to controls.